These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30526033)

  • 1. Novel non-nucleotidic STING agonists for cancer immunotherapy.
    Berger G; Lawler SE
    Future Med Chem; 2018 Dec; 10(24):2767-2769. PubMed ID: 30526033
    [No Abstract]   [Full Text] [Related]  

  • 2. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
    Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
    Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. piSTING: A Pocket-Independent Agonist Based on Multivalency-Driven STING Oligomerization.
    Zhuo SH; Wang TY; Zhao L; Su JY; Hu JJ; Zhao YF; Li YM
    Angew Chem Int Ed Engl; 2024 Sep; 63(38):e202407037. PubMed ID: 38767062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
    Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
    J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapy.
    Marloye M; Lawler SE; Berger G
    Pharm Pat Anal; 2019 Jul; 8(4):87-90. PubMed ID: 31354104
    [No Abstract]   [Full Text] [Related]  

  • 7. Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy.
    Waters CM
    Open Biol; 2021 Dec; 11(12):210277. PubMed ID: 34905701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy.
    Wu JJ; Zhao L; Hu HG; Li WH; Li YM
    Med Res Rev; 2020 May; 40(3):1117-1141. PubMed ID: 31793026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.
    Kuttruff CA; Fleck M; Carotta S; Arnhof H; Bretschneider T; Dahmann G; Gremel G; Grube A; Handschuh S; Heimann A; Hofmann MH; Impagnatiello MA; Nar H; Rast G; Schaaf O; Schmidt E; Oost T
    J Med Chem; 2023 Jul; 66(14):9376-9400. PubMed ID: 37450324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING Activation and its Application in Immuno-Oncology.
    Lian Y; Duffy KJ; Yang J
    Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
    Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
    Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
    Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
    Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pam
    Hu HG; Wu JJ; Zhang BD; Li WH; Li YM
    Bioconjug Chem; 2020 Nov; 31(11):2499-2503. PubMed ID: 33147965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STING Signaling in Cancer Cells: Important or Not?
    Sokolowska O; Nowis D
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):125-132. PubMed ID: 28748479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8
    Watkins-Schulz R; Tiet P; Gallovic MD; Junkins RD; Batty C; Bachelder EM; Ainslie KM; Ting JPY
    Biomaterials; 2019 Jun; 205():94-105. PubMed ID: 30909112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
    Corrales L; Gajewski TF
    Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of amidobenzimidazole STING receptor agonists with systemic activity.
    Ramanjulu JM; Pesiridis GS; Yang J; Concha N; Singhaus R; Zhang SY; Tran JL; Moore P; Lehmann S; Eberl HC; Muelbaier M; Schneck JL; Clemens J; Adam M; Mehlmann J; Romano J; Morales A; Kang J; Leister L; Graybill TL; Charnley AK; Ye G; Nevins N; Behnia K; Wolf AI; Kasparcova V; Nurse K; Wang L; Puhl AC; Li Y; Klein M; Hopson CB; Guss J; Bantscheff M; Bergamini G; Reilly MA; Lian Y; Duffy KJ; Adams J; Foley KP; Gough PJ; Marquis RW; Smothers J; Hoos A; Bertin J
    Nature; 2018 Dec; 564(7736):439-443. PubMed ID: 30405246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
    Corrales L; Gajewski TF
    Cytokine; 2016 Jan; 77():245-7. PubMed ID: 26315534
    [No Abstract]   [Full Text] [Related]  

  • 19. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases.
    Liu Y; Crowe WN; Wang L; Lu Y; Petty WJ; Habib AA; Zhao D
    Nat Commun; 2019 Nov; 10(1):5108. PubMed ID: 31704921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice.
    Skouboe MK; Knudsen A; Reinert LS; Boularan C; Lioux T; Perouzel E; Thomsen MK; Paludan SR
    PLoS Pathog; 2018 Apr; 14(4):e1006976. PubMed ID: 29608601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.